|
The CDC has issued a Health Alert Network (HAN) advisory regarding a measles outbreak in Texas and New Mexico. The alert includes clinical guidance, travel recommendations, and prevention strategies.
Key Recommendations for Healthcare Providers:
Ensure all patients without evidence of immunity, especially those traveling internationally, are up to date on MMR per ACIP recommendations:
- Children: 2 doses of MMR—first at 12–15 months, second at 4–6 years
- Infants (6–11 months): 1 dose prior to international travel. This dose does not count toward the routine 2-dose series
- Adults at low risk: 1 documented dose or other immunity evidence (e.g., positive IgG)
-
High-risk adults(e.g., healthcare workers, international travelers, students): 2 documented doses
- Residents in affected outbreak areas should follow local/state health guidance.
- All U.S. residents over 6 months traveling internationally should receive the MMR vaccine if not immune.
- Note: Mild rash post-vaccination may occur and is not typically infectious. If rash develops with a known or suspected measles exposure, consult your state or local health department.
Additional Resources:
With measles cases on the rise in 2025, including a significant outbreak in West Texas, this issue highlights 3 expert Q&As on measles and 12 on MMR vaccination, based on the latest ACIP guidance.
Access the full Q&A set here: immunize.org/ask-experts/topic/mmr
AIAW is just around the corner!
Held annually, AIAW highlights the importance of keeping adolescents up to date on their recommended vaccines. On-time immunization protects teens from serious illnesses and helps prevent missed school, sports, and social events.
Healthcare offices are encouraged to begin planning now.
Consider reaching out to families with reminders, scheduling vaccine catch-up visits, and preparing educational materials. Promoting AIAW helps ensure that Maine’s adolescents stay healthy and protected. |
We appreciate your efforts as we transition to new data loggers. Here are the latest updates:
-
Tier 1 Providers: Expected to be fully set up and running by Monday, March 31, 2025.
-
Tier 2 Providers: Devices have been received. Full setup must be completed by Friday, April 4, 2025.
-
Tier 3 Providers: Shipments will begin the first week of April.
Key Reminders:
- A training reminder email has been sent to all vaccine coordinators.
- Please be mindful of Control Solutions’ time zone (Pacific Time, 3 hours behind Maine).
- Step-by-step configuration guides (with screenshots) are available:
Need help?
Email: support@vfcdataloggers.com
Call: (503) 410-5996
Tier 2 Training Recording:
A recording of the Tier 2 training has been sent to all relevant vaccine coordinators.
Important:
If you received an email invitation to “Join Team,” please accept it. This is a necessary step before setting up the new data logger.
|
The RSV season for young children ends on March 31, 2025. Infants and children should receive nirsevimab only through this date.
All nirsevimab products in Maine expire in 2025. To prevent waste, any remaining inventory should be stored properly at the recommended temperature and monitored for use in the next RSV season.
Action Steps for Providers:
- Ensure all administered doses are recorded in ImmPact.
- Reconcile inventory to match what is documented in ImmPact.
- Store any remaining doses correctly and label them clearly to avoid mix-ups with other vaccines.
Thank you for your continued efforts to safely and effectively administer nirsevimab to Maine’s most vulnerable populations.
 |
